INS and breast cancer: Results demonstrate that breast cancer survivors, who are both centrally obese and insulin resistant, are characterised by greater metabolic dysfunction in terms of dyslipidemia, glucose dysmetabolism, raised CRP and a higher prevalence of the MetSyn compared to women who are centrally obese in the absence of insulin resistance.